Sio Gene Therapies (NASDAQ:SIOX) Vs. Organigram (NASDAQ:OGI) Head-To-Head Review
Sio Gene Therapies (NASDAQ:SIOX) Vs. Organigram (NASDAQ:OGI) Head-To-Head Review
Sio Gene Therapies (NASDAQ:SIOX – Get Rating) and Organigram (NASDAQ:OGI – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.
Sio Gene Therapies（纳斯达克股票代码：SIOX — 获取评级）和Organigram（纳斯达克股票代码：OGI — 获取评级）都是小型医疗公司，但哪只是优势股？我们将根据两家公司的收益、机构所有权、风险、估值、股息、盈利能力和分析师建议对两家公司进行比较。
Valuation and Earnings
估值和收益
This table compares Sio Gene Therapies and Organigram's top-line revenue, earnings per share (EPS) and valuation.
该表比较了Sio Gene Therapies和Organigram的最高收入、每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sio Gene Therapies | N/A | N/A | -$71.89 million | N/A | N/A |
| Organigram | $111.27 million | 1.81 | -$11.23 million | ($0.03) | -21.33 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| Sio 基因疗法 | 不适用 | 不适用 | -7189 万美元 | 不适用 | 不适用 |
| 组织结构图 | 1.1127 亿美元 | 1.81 | -1,123 万美元 | (0.03 美元) | -21.33 |
Organigram has higher revenue and earnings than Sio Gene Therapies.
Organigram的收入和收益高于Sio Gene Therapies。
Analyst Ratings
分析师评级
This is a breakdown of recent recommendations and price targets for Sio Gene Therapies and Organigram, as provided by MarketBeat.
这是MarketBeat提供的Sio Gene Therapies和Organigram的最新建议和目标价格的明细。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sio Gene Therapies | 1 | 1 | 0 | 0 | 1.50 |
| Organigram | 0 | 0 | 2 | 0 | 3.00 |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| Sio 基因疗法 | 1 | 1 | 0 | 0 | 1.50 |
| 组织结构图 | 0 | 0 | 2 | 0 | 3.00 |
Sio Gene Therapies presently has a consensus target price of $0.80, indicating a potential upside of 98.02%. Organigram has a consensus target price of $1.67, indicating a potential upside of 160.42%. Given Organigram's stronger consensus rating and higher possible upside, analysts plainly believe Organigram is more favorable than Sio Gene Therapies.
Sio Gene Therapies目前的共识目标价为0.80美元，表明潜在的上涨空间为98.02％。Organigram的共识目标价为1.67美元，表明潜在的上涨空间为160.42％。鉴于Organigram的共识评级更高，可能的上行空间也更高，分析师显然认为Organigram比Sio Gene Therapies更有利。
Profitability
盈利能力
This table compares Sio Gene Therapies and Organigram's net margins, return on equity and return on assets.
该表比较了Sio Gene Therapies和Organigram的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Sio Gene Therapies | N/A | -55.94% | -48.33% |
| Organigram | -4.97% | -6.00% | -5.30% |
| 净利润 | 股本回报率 | 资产回报率 | |
| Sio 基因疗法 | 不适用 | -55.94% | -48.33% |
| 组织结构图 | -4.97% | -6.00% | -5.30% |
Insider and Institutional Ownership
内部所有权和机构所有权
11.0% of Organigram shares are owned by institutional investors. 3.4% of Sio Gene Therapies shares are owned by company insiders. Comparatively, 0.1% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
11.0％的Organigram股份由机构投资者持有。3.4％的Sio Gene Therapies股份由公司内部人士持有。相比之下，有0.1％的Organigram股份由公司内部人士持有。强大的机构所有权表明，捐赠基金、大型基金经理和对冲基金认为，从长远来看，公司的表现将超过市场。
Summary
摘要
Organigram beats Sio Gene Therapies on 8 of the 10 factors compared between the two stocks.
与两只股票相比，Organigram在10个因素中的8个方面击败了Sio Gene Therapies。
About Sio Gene Therapies
关于 Sio 基因疗法
(Get Rating)
（获取评分）
Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focuses on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis, such as Tay-Sachs disease and Sandhoff disease. The company was founded on October 31, 2014 and is headquartered in New York, NY.
Sio Gene Therapies, Inc. 是一家处于临床阶段的生物制药公司，从事神经系统疾病基因疗法的收购、开发和商业化。其产品线侧重于帕金森氏病、GM1神经节苷脂病和GM2神经节苷脂症，例如泰萨克斯病和桑德霍夫病。该公司成立于2014年10月31日，总部位于纽约州纽约。
About Organigram
关于组织结构图
(Get Rating)
（获取评分）
OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. It focuses on producing cannabis for patients and adult recreational consumers. The firm's brands include Adult Recreational and Medical. The company was founded on July 5, 2010 and is headquartered in Moncton, Canada.
OrganiGram Holdings, Inc. 从事医用大麻的生产和销售。它专注于为患者和成人娱乐消费者生产大麻。该公司的品牌包括成人娱乐和医疗。该公司成立于2010年7月5日，总部位于加拿大蒙克顿。
Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Sio 基因疗法的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Sio Gene Therapies及相关公司的最新新闻和分析师评级的简明每日摘要。